Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

about

Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab.Necitumumab for non-small cell lung cancer.

P2860

Q38381681-12BA8B54-9E4F-4591-A89D-FD6B5CA9BD54 Q38519582-9623D0D7-ED3E-408C-B99E-2999C26835BD

P2860

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q52957112

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

@en

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

@nl

type

Item

label

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

@en

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

@nl

prefLabel

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

@en

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

@nl

P1476

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

@en

P2093

Assunta Sgambato

http://www.w3.org/2001/XMLSchema#string

Francesca Casaluce

http://www.w3.org/2001/XMLSchema#string

Giovanni Palazzolo

http://www.w3.org/2001/XMLSchema#string

Paola Claudia Sacco

http://www.w3.org/2001/XMLSchema#string

Paolo Maione

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Management and preparedness for infusion and hypersensitivity reactions.

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies.

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

EGFR and cancer prognosis.

Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

P304

245-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17476348.2015.1027688

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Rossi

Cesare Gridelli

P577

2015-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25797462

http://www.w3.org/2001/XMLSchema#string

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

about

P2860

P2860

Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698